Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anti-obesity drugs are widely used to prevent the complications of obesity, however, the effects of anti-obesity drugs on cardiovascular risk factors are unclear at the present time. We carried out a comprehensively systematic review and meta-analysis to assess the effects of anti-obesity drugs on cardiovascular risk factors. METHODOLOGY AND PRINCIPAL FINDINGS: We systematically searched Medline, EmBase, the Cochrane Central Register of Controlled Trials, reference lists of articles and proceedings of major meetings for relevant literatures. We included randomized placebo-controlled trials that reported the effects of anti-obesity drugs on cardiovascular risk factors compared to placebo. Overall, orlistat produced a reduction of 2.39 kg (95%CI-3.34 to -1.45) for weight, a reduction of 0.27 mmol/L (95%CI: -0.36 to -0.17) for total cholesterol, a reduction of 0.21 mmol/L (95%CI: -0.30 to -0.12) for LDL, a reduction of 0.12 mmol/L (95%CI: -0.20 to -0.04) for fasting glucose, 1.85 mmHg reduction (95%CI: -3.30 to -0.40) for SBP, and a reduction of 1.49 mmHg (95%CI: -2.39 to -0.58) for DBP. Sibutramine only showed effects on weight loss and triglycerides reduction with statistical significances. Rimonabant was associated with statistically significant effects on weight loss, SBP reduction and DBP reduction. No other significantly different effects were identified between anti-obesity therapy and placebo. CONCLUSION/SIGNIFICANCE: We identified that anti-obesity therapy was associated with a decrease of weight regardless of the type of the drug. Orlistat and rimonabant could lead to an improvement on cardiovascular risk factors. However, Sibutramine may have a direct effect on cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent meta-analysis concerning anti-obesity drugs reported a mean weight loss of 3.13 kg, but marked improvements in dyslipidemia were absent [134].”
From Dyslipidemia in obesity: Mechanisms and potential targets (2013) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
The Continuing Epidemics of Obesity and Diabetes in the United States
Mokdad, A. H. (2001) · JAMA · doi:10.1001/jama.286.10.1195 · Cited by 2,730
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 3×
“Among these included trials, 10 studies evaluated orlistat therapy [21–25,28,30,32–34], 3 [16,37,38] evaluated rimonabant therapy and remaining 8 [15,26,27,29,31,35,36,39] evaluated sibutramine therapy.”
BackgroundAnnual Deaths Attributable to Obesity in the United States
Allison, D. B. (1999) · JAMA · doi:10.1001/jama.282.16.1530 · Cited by 1,871 · cited 3×
“T Ja m e s( 2 0 0 0 ) [2 6 ] 4 6 7 4 0 .”
InfluentialVan Gaal, L. F., Rissanen, A. M., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,499
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
S UCCESSFUL W EIGHT L OSS M AINTENANCE
Wing, R. R., & Hill, J. O. (2001) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.21.1.323 · Cited by 1,382 · cited 1×
“Lifestyle modifications are not sufficient impact on weight loss and attentions have been drawn to additional effective prevention therapies [7–12].”
BackgroundBeneficial health effects of modest weight loss.
Dj, G. (1992) · PubMed · Cited by 1,263
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Overweight, Obesity, and Health Risk
(2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.7.898 · Cited by 964
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943
The Interpretation of Random-Effects Meta-Analysis in Decision Models
Ades, A. E., Lu, G., & Higgins, J. P. T. (2005) · Medical Decision Making · doi:10.1177/0272989x05282643 · Cited by 859
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817 · cited 1×
“Among these included trials, 10 studies evaluated orlistat therapy [21–25,28,30,32–34], 3 [16,37,38] evaluated rimonabant therapy and remaining 8 [15,26,27,29,31,35,36,39] evaluated sibutramine therapy.”
BackgroundChanoine, J.-P., Hampl, S., Jensen, C., Boldrin, M., & Hauptman, J. (2005) · JAMA · doi:10.1001/jama.293.23.2873 · Cited by 624
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476 · cited 3×
“Among these included trials, 10 studies evaluated orlistat therapy [21–25,28,30,32–34], 3 [16,37,38] evaluated rimonabant therapy and remaining 8 [15,26,27,29,31,35,36,39] evaluated sibutramine therapy.”
BackgroundJousilahti, P., Tuomilehto, J., Vartiainen, E., Pekkanen, J., & Puska, P. (1996) · Circulation · doi:10.1161/01.cir.93.7.1372 · Cited by 401
Berkowitz, R. I., Wadden, T. A., Tershakovec, A. M., & Cronquist, J. L. (2003) · JAMA · doi:10.1001/jama.289.14.1805 · Cited by 389
Kramer, F. M., Jeffery, R. W., Forster, J. L., & Snell, M. K. (1989) · PubMed · Cited by 378
Ayyad, C., & Andersen, T. (2000) · Obesity Reviews · doi:10.1046/j.1467-789x.2000.00019.x · Cited by 355
Finer, N., James, W., Kopelman, P., Lean, M., & Williams, G. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801128 · Cited by 325
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.6.1108 · Cited by 287 · cited 3×
“Among these included trials, 10 studies evaluated orlistat therapy [21–25,28,30,32–34], 3 [16,37,38] evaluated rimonabant therapy and remaining 8 [15,26,27,29,31,35,36,39] evaluated sibutramine therapy.”
BackgroundLong-term Weight Loss With Sibutramine: A Randomized Controlled Trial
Wirth, A., & Krause, J. (2001) · JAMA · doi:10.1001/jama.286.11.1331 · Cited by 272
for the OBES-002 Study Group, Wilding, J., Gaal, L. V., Rissanen, A., Vercruysse, F., & Fitchet, M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802783 · Cited by 224
Lindgärde, F. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00720.x · Cited by 204
Després, J.-P., Ross, R., Boka, G., Alméras, N., & Lemieux, I. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.176362 · Cited by 200
Treatment of Obese Adolescents with Sibutramine: A Randomized, Double-Blind, Controlled Study
Godoy-Matos, A., Carraro, L., Vieira, A., Oliveira, J., Guedes, E. P., Mattos, L., Rangel, C., Moreira, R. O., Coutinho, W., & Appolinario, J. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0263 · Cited by 158
Fluoxetine: a randomized clinical trial in the treatment of obesity.
GOLDSTEIN, D. J., Rampey, A. H., Enas, G. G., Potvin, J. H., Fludzinski, L. A., & Levine, L. R. (1994) · PubMed · Cited by 155
Richelsen, B., Tonstad, S., Rössner, S., Toubro, S., Niskanen, L., Madsbad, S., Mustajoki, P., & Rissanen, A. (2007) · Diabetes Care · doi:10.2337/dc06-0210 · Cited by 149
Broom, I., Wilding, J., Stott, P., Myers, N., & UK Multimorhidity Study Group (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11307.x · Cited by 103
Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity
Krempf, M., Jp, L., Allanic, H., Miloradovich, T., Joubert, J., & Attali, J. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802281 · Cited by 95 · cited 3×
“Among these included trials, 10 studies evaluated orlistat therapy [21–25,28,30,32–34], 3 [16,37,38] evaluated rimonabant therapy and remaining 8 [15,26,27,29,31,35,36,39] evaluated sibutramine therapy.”
BackgroundToplak, H., Ziegler, O., Keller, U., Hamann, A., Godin, C., Wittert, G., Zanella, M. ‐., Zúñiga‐Guajardo, S., & Van Gaal, L. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00483.x · Cited by 86
Effect of orlistat on cardiovascular disease risk in obese adults
Swinburn, B. A., Carey, D., Hills, A. P., Hooper, M., Marks, S., Proietto, J., Strauss, B. J., Sullivan, D., Welborn, T. A., & Caterson, I. D. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00467.x · Cited by 81 · cited 2×
“Due to the fact that the cardiovascular risk factors were increased in patients with diabetes mellitus, hyperlipidaemia, hyperglycemia, and hypertension [44,45], we therefore restricted inclusion criteria to ensure our study to explore the effects of antiobesity drugs on cardiovascular risk factors.”
BackgroundWeight Reduction by Sibutramine in Obese Subjects in Primary Care Medicine: The S. A. T. Study
Hauner, H., Meier, M., Wendland, G., Kurscheid, T., & Lauterbach, K. (2004) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2004-817934 · Cited by 72
García-Morales, L. M., Berber, A. C., Macias-Lara, C. C., Lucio-Ortiz, C., Del-Rio-Navarro, B. E., & Dorantes-Alvarez, L. M. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.05.008 · Cited by 72 · cited 1×
“Among these included trials, 10 studies evaluated orlistat therapy [21–25,28,30,32–34], 3 [16,37,38] evaluated rimonabant therapy and remaining 8 [15,26,27,29,31,35,36,39] evaluated sibutramine therapy.”
BackgroundCzernichow, S., Lee, C., Barzi, F., Greenfield, J. R., Baur, L. A., Chalmers, J. P., Woodward, M., & Huxley, R. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00620.x · Cited by 60 · cited 2×
“Previous review [14] only provided evidence that anti-obesity drugs have a role in weight loss for obese adolescents, but did not provide clear evidence showing whether anti-obesity therapy was associated with effects on cardiovascular risk factors.”
BackgroundResultWeight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification
Poston, W. S. C., Reeves, R. S., Haddock, C. K., Stormer, S., Balasubramanyam, A., Satterwhite, O., Taylor, J. E., & Foreyt, J. P. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802439 · Cited by 54 · cited 1×
“However, the effects of anti-obesity drugs on cardiovascular risk factors remain unclear [7,13].”
BackgroundDaniels, S. R., Long, B., Crow, S., Styne, D., Sothern, M., Vargas-Rodriguez, I., Harris, L., Walch, J., Jasinsky, O., Cwik, K., et al. (2007) · Pediatrics · doi:10.1542/peds.2006-2137 · Cited by 52
Anderson, J. W., Schwartz, S. M., Hauptman, J., Boldrin, M., Rossi, M., Bansal, V., & Hale, C. A. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h234 · Cited by 51
POSTON, W. S. C., HADDOCK, C. K., PINKSTON, M. M., PACE, P., REEVES, R. S., KARAKOC, N., JONES, P., & FOREYT, J. P. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01702.x · Cited by 46
Fluoxetine: A Randomized Clinical Trial in the Maintenance of Weight Loss
GOLDSTEIN, D. J., Rampey, A. H., Dornseif, B. E., Levine, L. R., Potvin, J. H., & Fludzinski, L. A. (1993) · Obesity Research · doi:10.1002/j.1550-8528.1993.tb00597.x · Cited by 38
Long-term weight loss with sibutramine. A randomized controlled trial
Wirth, A. G., & Krause, J. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00555-4 · Cited by 34
Porter, J. A., Raebel, M. A., Conner, D. A., Lanty, F. A., Vogel, E. A., Gay, E. C., & Merenich, J. A. (2004) · PubMed · Cited by 32
Obesity Management Interventions: A Review of the Evidence
Yaskin, J. C., Toner, R. W., & Goldfarb, N. I. (2009) · Population Health Management · doi:10.1089/pop.2008.0049 · Cited by 32
Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects
SIMONE, G. D., Romano, C., Caprio, C. D., Contaldo, F., Salanitri, T., Paparatti, U. D. L., & Pasanisi, F. (2005) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2004.07.002 · Cited by 25
Tesofensine – a novel potent weight loss medicine
Doggrell, S. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902967632 · Cited by 17
The obese older female patient: CV risk and the SCOUT study
Coutinho, W. F. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803733 · Cited by 8
Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell, S. A. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.12.2141 · Cited by 1
Cited by
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“13 mmol/L reduction in TG, whereas rimonabant did not show any lipid improvements [134].”
BackgroundAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
“Nonetheless, even among older and withdrawn weight management drugs, the potential of such agents in improving health was supported by improvements in lipid levels, as well as improvement in other metabolic parameters.(253) The rimonobant development program is illustrative of both the promise and the challenges in ch…”
BackgroundDrugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
Domecq, J. P., Prutsky, G., Leppin, A., Sonbol, M. B., Altayar, O., Undavalli, C., Wang, Z., Elraiyah, T., Brito, J. P., Mauck, K. F., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3421 · Cited by 334
Metadata
- Authors
- Zhou, Y.-H., Ma, X.-Q., Wu, C., Lu, J., Zhang, S.-S., Guo, J., Wu, S.-Q., Ye, X.-F., Xu, J.-F., & He, J.
- Affiliations
- Second Military Medical University (CN)
- Corresponding author
- He, Jia
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-06-20
- Volume
- 7
- Issue
- 6
- Pages
- e39062
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3380040
- OpenAlex
- W2163687543
- Cited by
- 84
- References
- 57
- Citations by year
- 2025: 2 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 6 · 2018: 5 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 10 · 2013: 13
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Natural Science Foundation of China
- Program of Shanghai Subject Chief Scientist
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- anti-obesity drugs, cardiovascular risk factors, orlistat, sibutramine, rimonabant, weight loss, blood pressure, cholesterol, triglycerides, fasting blood glucose, obesity
- MeSH terms
- Cardiovascular Diseases, Humans, Obesity, Weight Loss, Randomized Controlled Trials as Topic, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.